Related Experiment Video
Updated: Mar 18, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection
Alireza FakhriRavari1, Mazyar Malakouti2, Rebecca Brady1
1Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USA.
Insights
New direct-acting agents offer effective, tolerable, and shorter treatments for Hepatitis C virus (HCV) genotype 1 infections, improving patient adherence and outcomes compared to older therapies.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection impacts 185 million globally, leading to severe liver disease and death without transplant.
- HCV genotype 1 is prevalent in the US, accounting for 75% of infections.
- Traditional interferon and ribavirin therapy is being replaced by more effective treatments.
Purpose of the Study:
- To review current combination therapies for HCV genotype 1.
- To summarize emerging direct-acting agent therapies in phase 3 trials.
Main Methods:
- Systematic review of clinical trial data.
- Evidence synthesis of direct-acting agent efficacy and safety.
Main Results:
- Interferon-free treatments demonstrate higher efficacy and better tolerability.
- Shorter treatment durations and reduced pill burden improve patient adherence.
- Emerging therapies show promise for further improving treatment outcomes.
Conclusions:
- Direct-acting agents represent a significant advancement in HCV genotype 1 treatment.
- Current and emerging therapies offer improved patient outcomes and quality of life.
- Continued research is vital for optimizing HCV management.
Abstract:
Hepatitis C virus (HCV) infection affects as many as 185 million people globally, many of whom are chronically infected and progress over time to cirrhosis, decompensated liver disease, hepatocellular carcinoma, and eventually death without a liver transplant. In the United States, HCV genotype 1 constitutes about 75% of all infections. While interferon and ribavirin therapy was the cornerstone of treatment for many years, interferon-free treatments have become the standard of care with the emergence of new direct-acting agents, resulting in more effective treatment, shorter duration of therapy, better tolerability, lower pill burden, and ultimately better adherence. This review will summarize the evidence for the currently available combination therapies as well as emerging therapies in phase 3 trials for treatment of HCV genotype 1.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viruses with RNA Genomes
Retrovirus Life Cycles

